

Global Autologous Cell Therapy Market Report and Forecast 2024-2032

Market Report | 2023-10-01 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

Report description:

Global Autologous Cell Therapy Market Report and Forecast 2024-2032

Global Autologous Cell Therapy Market Outlook

The global autologous cell therapy market size was valued at USD 7.8 billion in 2023, driven by the increasing prevalence of chronic diseases, cancer, and a growing focus on personalized medicine across the globe. The market size is anticipated to grow at a CAGR of 19.4% during the forecast period of 2024-2032 to achieve a value of USD 38.4 billion by 2032.

Autologous Cell Therapy: Introduction

Autologous cell therapy represents a cutting-edge and personalized approach in the field of regenerative medicine and treatment of various diseases. This therapeutic method involves harvesting cells from a patient's own body, manipulating or culturing them in a controlled environment, and then reintroducing them into the patient's body to achieve a therapeutic effect. The key advantage of autologous cell therapy is the significantly reduced risk of immune rejection, as the cells originate from the patient. This therapy has been explored and applied in a wide range of medical fields, including oncology for cancer treatment, particularly with the advent of CAR-T cell therapies, in regenerative medicine for repairing damaged tissues, and in the treatment of autoimmune diseases.

Autologous cell therapy represents a leap forward in personalized medicine, offering targeted and individualized treatment options based on a patient's unique cellular makeup, potentially leading to more effective and safer treatments compared to conventional methods.

Key Trends in the Global Autologous Cell Therapy Market

The global autologous cell therapy market was witnessing several key trends shaping its growth and development. Firstly, there was a substantial increase in clinical research and trials, focusing on the potential of autologous cell therapies in treating a wide

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

range of diseases, including various forms of cancer, degenerative diseases, and autoimmune disorders. This was coupled with significant advancements in cell culturing techniques and genetic engineering, leading to more effective and targeted therapies. Personalized medicine was at the forefront, with a growing emphasis on developing treatments tailored to individual patients' genetic and cellular profiles. Regulatory agencies were increasingly recognizing and approving autologous cell therapies, providing a framework for safe and controlled application.

Additionally, there was a trend towards partnerships and collaborations between biotech companies, academic institutions, and healthcare providers, aimed at accelerating research and expanding treatment accessibility. Despite these positive trends, the market faced challenges such as high costs of therapy development and delivery, complex manufacturing processes, and the need for specialized healthcare infrastructure. Nevertheless, these trends were indicative of a dynamic and evolving market, with autologous cell therapy being viewed as a promising frontier in modern medicine.

Global Autologous Cell Therapy Market Segmentation

Market Breakup by Therapy

- Autologous Stem Cell Therapy
- Autologous Cellular Immunotherapies

Market Breakup by Source

- Bone Marrow
- Epidermis
- Others

Market Breakup by Application

- Oncology
- Musculoskeletal Disorder
- Blood Disorder
- Autoimmune Disease
- Others

Market Breakup by End User

- Hospitals
- Research Centres
- Cancer Treatment Centres
- Others

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global Autologous Cell Therapy Market Overview

The global autologous cell therapy market was a rapidly evolving and promising segment in the field of advanced therapeutics. This market's growth was primarily driven by the increasing prevalence of chronic diseases, cancer, and a growing focus on

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

personalized medicine. North America was a leading market, attributed to its advanced healthcare infrastructure, substantial investments in research and development, and supportive regulatory environment. Europe also held a significant market share, with ongoing clinical trials and growing adoption of innovative therapies. Meanwhile, the Asia Pacific region was emerging as a fast-growing market, driven by rising healthcare spending, increasing prevalence of chronic diseases, and expanding healthcare infrastructure.

The autologous cell therapy market growth was characterized by intense research activities, with numerous clinical trials exploring the efficacy of autologous cell therapies in various medical conditions. Companies in this space were heavily investing in developing new therapies and improving manufacturing processes. Despite the significant potential, the market faced challenges such as high treatment costs, complex manufacturing and logistics, and stringent regulatory requirements. Nonetheless, the global Autologous Cell Therapy market was anticipated to continue its growth trajectory, fueled by the pressing need for more effective and personalized treatment options in healthcare.

Global Autologous Cell Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- [] Sanpower Group (Dendreon Pharmaceuticals LLC.)
- [] Holostem Terapie Avanzate S.r.l.
- [] Novartis AG
- [] Tego Science
- [] GC Biopharma (GC Cell)
- [] Gilead Sciences
- [] Johnson & Johnson (Janssen Biotech, Inc)
- [] Bristol Myers Squibb
- [] CORESTEM, Inc
- [] Vericel Corporation
- [] Opexa Therapeutics
- [] Lineage Cell Therapeutics, Inc.
- [] Pharmicell Co., Inc.

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Autologous Cell Therapy Market Overview
 - 3.1 Global Autologous Cell Therapy Market Historical Value (2017-2023)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.2 Global Autologous Cell Therapy Market Forecast Value (2024-2032)
- 4 Global Autologous Cell Therapy Market Landscape
 - 4.1 Global Autologous Cell Therapy Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Autologous Cell Therapy Product Landscape
 - 4.2.1 Analysis by Therapy
 - 4.2.2 Analysis by Source
 - 4.2.3 Analysis by Application
- 5 Global Autologous Cell Therapy Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Autologous Cell Therapy Market Segmentation
 - 6.1 Global Autologous Cell Therapy Market by Therapy
 - 6.1.1 Market Overview
 - 6.1.2 Autologous Stem Cell Therapy
 - 6.1.3 Autologous Cellular Immunotherapies
 - 6.2 Global Autologous Cell Therapy Market by Source
 - 6.2.1 Market Overview
 - 6.2.2 Bone Marrow
 - 6.2.3 Epidermis
 - 6.2.4 Others
 - 6.3 Global Autologous Cell Therapy Market by Application
 - 6.3.1 Market Overview
 - 6.3.2 Oncology
 - 6.3.3 Musculoskeletal Disorder
 - 6.3.4 Blood Disorder
 - 6.3.5 Autoimmune Disease
 - 6.3.6 Others
 - 6.4 Global Autologous Cell Therapy Market by End User
 - 6.4.1 Market Overview
 - 6.4.2 Hospitals
 - 6.4.3 Research Centers
 - 6.4.4 Cancer Treatment Centres
 - 6.4.5 Others
 - 6.5 Global Autologous Cell Therapy Market by Region
 - 6.5.1 Market Overview
 - 6.5.2 North America
 - 6.5.3 Europe
 - 6.5.4 Asia Pacific
 - 6.5.5 Latin America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.5.6 Middle East and Africa
- 7 North America Autologous Cell Therapy Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Autologous Cell Therapy Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Autologous Cell Therapy Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia
 - 9.7 Others
- 10 Latin America Autologous Cell Therapy Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Autologous Cell Therapy Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by Year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
 - 14.1 Analysis by Trial Registration Year
 - 14.2 Analysis by Trial Status
 - 14.3 Analysis by Trial Phase
 - 14.4 Analysis by Therapeutic Area
 - 14.5 Analysis by Geography
- 15 Funding & Investment Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding
 - 15.3 Analysis by Funding Amount
 - 15.4 Analysis by Leading Players
 - 15.5 Analysis by Leading Investors
 - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership
 - 16.3 Analysis by Leading Players
 - 16.4 Analysis by Geography
- 17 Regulatory Framework
 - 17.1 Regulatory Overview
 - 17.1.1 US FDA
 - 17.1.2 EU EMA
 - 17.1.3 INDIA CDSCO
 - 17.1.4 JAPAN PMDA
 - 17.1.5 Others
- 18 Supplier Landscape
 - 18.1 Sanpower Group (Dendreon Pharmaceuticals LLC.)
 - 18.1.1 Financial Analysis
 - 18.1.2 Product Portfolio
 - 18.1.3 Demographic Reach and Achievements
 - 18.1.4 Mergers and Acquisitions
 - 18.1.5 Certifications
 - 18.2 Holostem Terapie Avanzate S.r.l.
 - 18.2.1 Financial Analysis
 - 18.2.2 Product Portfolio
 - 18.2.3 Demographic Reach and Achievements
 - 18.2.4 Mergers and Acquisitions
 - 18.2.5 Certifications
 - 18.3 Novartis AG
 - 18.3.1 Financial Analysis
 - 18.3.2 Product Portfolio
 - 18.3.3 Demographic Reach and Achievements
 - 18.3.4 Mergers and Acquisitions
 - 18.3.5 Certifications
 - 18.4 Tego Science

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.4.1 Financial Analysis
- 18.4.2 Financial Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 GC Biopharma (GC Cell)
 - 18.5.1 Financial Analysis
 - 18.5.2 Product Portfolio
 - 18.5.3 Demographic Reach and Achievements
 - 18.5.4 Mergers and Acquisitions
 - 18.5.5 Certifications
- 18.6 Gilead Sciences
 - 18.6.1 Financial Analysis
 - 18.6.2 Product Portfolio
 - 18.6.3 Demographic Reach and Achievements
 - 18.6.4 Mergers and Acquisitions
 - 18.6.5 Certifications
- 18.7 Johnson & Johnson (Janssen Biotech, Inc)
 - 18.7.1 Financial Analysis
 - 18.7.2 Product Portfolio
 - 18.7.3 Demographic Reach and Achievements
 - 18.7.4 Mergers and Acquisitions
 - 18.7.5 Certifications
- 18.8 Bristol Myers Squibb
 - 18.8.1 Financial Analysis
 - 18.8.2 Product Portfolio
 - 18.8.3 Demographic Reach and Achievements
 - 18.8.4 Mergers and Acquisitions
 - 18.8.5 Certifications
- 18.9 CORESTEM, Inc
 - 18.9.1 Financial Analysis
 - 18.9.2 Product Portfolio
 - 18.9.3 Demographic Reach and Achievements
 - 18.9.4 Mergers and Acquisitions
 - 18.9.5 Certifications
- 18.10 Vericel Corporation
 - 18.10.1 Financial Analysis
 - 18.10.2 Product Portfolio
 - 18.10.3 Demographic Reach and Achievements
 - 18.10.4 Mergers and Acquisitions
 - 18.10.5 Certifications
- 18.11 Opexa Therapeutics
 - 18.11.1 Financial Analysis
 - 18.11.2 Product Portfolio
 - 18.11.3 Demographic Reach and Achievements
 - 18.11.4 Mergers and Acquisitions
 - 18.11.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.12 Lineage Cell Therapeutics, Inc.
 - 18.12.1 Financial Analysis
 - 18.12.2 Product Portfolio
 - 18.12.3 Demographic Reach and Achievements
 - 18.12.4 Mergers and Acquisitions
 - 18.12.5 Certifications
- 18.13 Pharmicell Co., Inc.
 - 18.13.1 Financial Analysis
 - 18.13.2 Product Portfolio
 - 18.13.3 Demographic Reach and Achievements
 - 18.13.4 Mergers and Acquisitions
 - 18.13.5 Certifications
- 19 Global Autologous Cell Therapy Market - Distribution Model (Additional Insight)
 - 19.1 Overview
 - 19.2 Potential Distributors
 - 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
 - 21.1 Very Small Companies
 - 21.2 Small Companies
 - 21.3 Mid-Sized Companies
 - 21.4 Large Companies
 - 21.5 Very Large Companies
- 22 Payment Methods (Additional Insight)
 - 22.1 Government Funded
 - 22.2 Private Insurance
 - 22.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Global Autologous Cell Therapy Market Report and Forecast 2024-2032

Market Report | 2023-10-01 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com